Targets › BZLF1
2 programs from 2 companies in 4 trials: 4 Phase 1; Infectious disease, Genitourinary; next expected readout May 2027.
Open in Phaseline: the race on BZLF1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| ModernaTX | mRNA-1189 mRNA vaccine encoding Epstein-Barr virus antigens | EBNA1, LMP1, BZLF1 | Phase 1 | Epstein-Barr Virus Infection; Epstein-Barr Virus | May 2027 |
| Ohio State University Comprehensive Cancer Center | OSU-2131 BZLF1 peptide vaccine (rh-Hsc70-BZLF1 peptide complex) | BZLF1 | Phase 1 | Chronic Kidney Disease, Stage 4 | Jul 2027 |
Epstein-Barr Virus Infection (2) Epstein-Barr Virus (1) Chronic Kidney Disease, Stage 4 (1)
other (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.